The impact of single-hetero UGT1A1 on clinical outcomes of irinotecan monotherapy in gastric cancer after fluoropyrimidine, platinum, and taxanes: Multicenter retrospective study.

Ken Ito,Yoshito Komatsu,Satoshi Yuki,Shintaro Nakano,Hiroshi Nakatsumi,Yasuyuki Kawamoto,Tetsuhito Muranaka,Kentaro Sawada,Takayuki Ando,Shinya Kajiura,Takuto Miyagishima,Kazuaki Harada,Yoshimitsu Kobayashi,Kazuteru Hatanaka,Atsushi Ishiguro,Takuya Honda,Masayoshi Dazai,Takahide Sasaki,Naoya Sakamoto

The impact of single-hetero UGT1A1 on clinical outcomes of irinotecan monotherapy in gastric cancer after fluoropyrimidine, platinum, and taxanes: Multicenter retrospective study.

2020

Ken Ito
Yoshito Komatsu
Satoshi Yuki
Shintaro Nakano
Hiroshi Nakatsumi
Yasuyuki Kawamoto
Tetsuhito Muranaka
Kentaro Sawada
Takayuki Ando
Shinya Kajiura
Takuto Miyagishima
Kazuaki Harada
Yoshimitsu Kobayashi
Kazuteru Hatanaka
Atsushi Ishiguro
Takuya Honda
Masayoshi Dazai
Takahide Sasaki
Naoya Sakamoto

296Background: Japanese gastric cancer treatment guidelines (5th edition) recommend irinotecan (IRI) after fluoropyrimidine, platinum and taxanes as a third line chemotherapy. We previously reporte...

Keywords:

Internal medicine
Irinotecan
Cancer
Medicine
Oncology
Retrospective cohort study
Pathology
cancer treatment
third line chemotherapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations